Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Sep 15;7(9):7821–7841. doi: 10.3390/nu7095369

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 by the authors; licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effects of the treatments on diabetes induced retinal p38 MAPK and NF-κB activation. STZ-diabetic rats (STZ) were administered 200 mg/kg/day ZZRext (ZZRext 200), 300 mg/kg/day ZZRext (ZZRext 300) or 500 mg/kg calcium dobesilate (CaD) by oral gavage once daily for three months. Another group of STZ-diabetic rats and normal rats (normal) were administered the same volume. (A) The activation of p38 MAPK was determined by Western blotting, analyzing the phospho-p38/p38 MAPK ratio. (B) NF-κB activation was determined in retinal homogenates by ELISA using an antibody specific for the p65 subunit of NF-κB. Data are mean ± S.D. (Standard Deviation) from eight rats per group, and the experiments were repeated independently at least three times with similar results. * p < 0.05 compared to the values of vehicle-treated normal rats. # p < 0.05 compared to the values of vehicle-treated STZ-diabetic rats.

Effects of the treatments on diabetes induced retinal p38 MAPK and NF-κB activation. STZ-diabetic rats (STZ) were administered 200 mg/kg/day ZZRext (ZZRext 200), 300 mg/kg/day ZZRext (ZZRext 300) or 500 mg/kg calcium dobesilate (CaD) by oral gavage once daily for three months. Another group of STZ-diabetic rats and normal rats (normal) were administered the same volume. (A) The activation of p38 MAPK was determined by Western blotting, analyzing the phospho-p38/p38 MAPK ratio. (B) NF-κB activation was determined in retinal homogenates by ELISA using an antibody specific for the p65 subunit of NF-κB. Data are mean ± S.D. (Standard Deviation) from eight rats per group, and the experiments were repeated independently at least three times with similar results. * p < 0.05 compared to the values of vehicle-treated normal rats. # p < 0.05 compared to the values of vehicle-treated STZ-diabetic rats.